Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

M.H.G. Langenberg, P.O. Witteveen, J.M.L. Roodhart, H.M.W. Verheul, M. Mergui-Roelvink, J. van der Sar, E. Brendel, N. Laferriere, J.H.M. Schellens, E.E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2187-2197
Number of pages11
JournalClinical Cancer Research
Issue number7
Publication statusPublished - 2010

Cite this